(Q41489415)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Antonio Craxì

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Massimo Iavarone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Giuseppe Cabibbo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Giuseppe Cabibbo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Marco Biolato

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Antonio Grieco

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Cristina Della Corte

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Marco Barbara

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Michele Basso

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sara Vavassori

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Carlo Cammà

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Massimo Colombo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

20 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

784-791

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25645399%20AND%20SRC:MED&resulttype=core&format=json

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

29 February 2020

cites work

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

21 January 2018

1 reference

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

21 January 2018

1 reference

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

21 January 2018

1 reference

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.

21 January 2018

1 reference

Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy

21 January 2018

1 reference

Time-dependent covariates in the Cox proportional-hazards regression model

21 January 2018

1 reference

When progressive disease does not mean treatment failure: reconsidering the criteria for progression

21 January 2018

1 reference

Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma

21 January 2018

1 reference

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

Systemic therapy in HCC: lessons from brivanib.

21 January 2018

1 reference

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

21 January 2018

1 reference

Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects

21 January 2018

1 reference